Status:
NOT_YET_RECRUITING
MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma
Lead Sponsor:
Sun Yat-sen University
Conditions:
Advanced Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using pub...
Detailed Description
This retrospective MAIC analysis employs individual patient data (IPD) from the FRUTIGA trial (fruquintinib arm) and published aggregate data (AgD) from RAINBOW-Asia (ramucirumab arm), with placebo as...
Eligibility Criteria
Inclusion
- Histologically confirmed gastric/GEJ adenocarcinoma
- Advanced or metastatic disease
- ECOG 0-1
- Received either fruquintinib + paclitaxel or reference regimen
- Available baseline characteristics for matching variables
Exclusion
- Missing key outcome data
- Incomplete baseline characteristics for \>2 matching variables
- Prior fruquintinib exposure (control arm only)
Key Trial Info
Start Date :
September 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
1143 Patients enrolled
Trial Details
Trial ID
NCT07144995
Start Date
September 5 2025
End Date
December 31 2026
Last Update
August 28 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.